Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 904-916

  Gimeno Ballester, V ^a,b   Buti, M ^c   San Miguel, R ^b,d   Riveiro, M ^c   Esteban, R ^c  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

chronic hepatitis C; direct antiviral agents; drug therapy; sustained virological response; systematic review; viral hepatitis

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DIRECT ACTING ANTIVIRAL; GLECAPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; PIBRENTASVIR; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; UNCLASSIFIED DRUG; VOXILAPREVIR;

CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; GENOTYPE; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDEPENDENT VARIABLE; LIVER CIRRHOSIS; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPACIVIRUS; META ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85030990115     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12660     Document Type: Review

References (43)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
2. Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666.
3. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98–105.
4. European Medicines Agency. Epclusa [Internet]. Product Information. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004210/human_med_001997.jsp&mid=WC0b01ac058001d124. Cited 2016 September 26.
5. European Medicines Agency. Harvoni [Internet]. Product Information. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003850/human_med_001813.jsp&mid=WC0b01ac058001d124. Cited 2016 September 26.
6. Moher D, Liberati A, Altman DG, Tetzlaff J, et al. Academia and Clinic Annals of Internal Medicine Preferred Reporting Items for Systematic Reviews and Meta-AnalysesThe PRISMA Statement. Ann Intern Med. 2009;151:264–269.
7. Mendeley: Free reference manager and PDF organizer [Internet]. 2016. http://www.mendeley.com/. Cited 2016 June 4.
8. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
9. Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62:1253–1260.e4.
10. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B,et al. Oxford centre for evidence-based medicine levels of evidence [Internet]. 2001 [cited 2016 Aug 24]. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
11. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
13. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014/05/06. 2014;370:1993–2001.
14. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with Hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462–1470.
15. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis. 2016;63:776–783.
16. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national healthcare system. Gastroenterology 2016;151:457–471.e5.
17. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127–1135.
18. Leroy V, Angus P, Bronowicki J-PJ-P, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016 May;63:1430–1441.
19. Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015;62:314A–314A.
20. Feld J, Ramji A, Shafran S, et al. Ledipasvir/sofosbuvir with ribavirin for 12 weeks is effective and safe in treatment-naïve genotype-3 hepatitis c-infected patients in Canada. J Hepatol. 2016;64:S781.
21. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015;149:1454–1461.e1.
22. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
23. Gane EJ, Hyland RH, An D, et al. Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study. Hepatology 2014;60:236A–237A.
24. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection a randomized trial. Ann Intern Med. 2015;163:809–817.
25. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV Genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
26. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
27. Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program. Hepatology 2015;62:225A–226A.
28. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Nov 7;65:1861–1870.
29. Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
30. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353.
31. Molina J-MM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098–1106.
32. Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study. J Hepatol. 2016;64:S188–S189.
33. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373:714–725.
34. Poordad F, Landis CS, Asatryan A, et al. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int 2016 Aug. 2016;36:1125–1132.
35. Lawitz E, Sullivan G, Rodriguez-Torres M, et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70:197–205.
36. Poordad F, Lawitz E, Gutierrez JA, et al. C-SWIFT: grazoprevir/elbasvir plus sofosbuvir in cirrhotic and noncirrhotic treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 OR 8 weeks and genotype 3 infection for durations of 8 and 12 weeks. J Hepatol. 2015;62:S192–S193.
37. Gane E, Kowdley KV, Pound D, Stedman CAM, Davis M, Etzkorn K, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with HCV genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 2016;151:902–909.
38. Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology 2016;151:448–456.
39. Kwo P, Bennett M, Wang S, et al. SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 In Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection. [Internet]. HEPDART 2015: Frontiers in Drug Development for Viral Hepatitis. Wailea, Hawaii 2015. Available from: http://www.natap.org/2015/hepDART/hepDART_11.htm.
40. Muir AJ, Strasser S, Wang S, et al. High SVR rates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection. In: 51st EASL; Barcelona, Spain; April 13-17, 2016. 2016.
41. Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 2016;151:651–659.
42. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–954.
43. Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis c virus infection and factors associated of sustained virologic response. Gastroenterology 2016Dec;151:1131–1140.